Drug intelligence / Profile preview

AJV

Development stage: Unknown
Lead developer: AJ Vaccines
Modality: Vaccines & Immunotherapeutics
Administration: Injection

Overview

AJV is identified as a component within the investigational vaccine "IPV-Al AJV (Picovax®)", which is designed to provide immunity against poliomyelitis. This vaccine, containing AJV, aims to induce antibody production against poliovirus types 1, 2, and 3. Clinical trials have evaluated its efficacy in previously immunized children, assessing the persistence of immunity and booster responses.

Beyond the preview

Go deeper on AJV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AJV.

Explore the full profile